ID   HEC-116
AC   CVCL_2924
SY   HEC116
DR   BioSample; SAMN03470936
DR   cancercelllines; CVCL_2924
DR   Cosmic; 1223495
DR   Cosmic; 1696748
DR   Cosmic; 2030467
DR   DepMap; ACH-001518
DR   IARC_TP53; 20592
DR   JCRB; JCRB1124
DR   JCRB; NIHS0395
DR   Wikidata; Q54882255
RX   DOI=10.1007/978-4-431-53981-0_1;
RX   PubMed=2064198;
RX   PubMed=15053063;
RX   PubMed=25877200;
RX   PubMed=28196595;
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Doubling time: 27.2 hours (PubMed=2064198).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg173Cys (c.517C>T); ClinVar=VCV000189500; Zygosity=Unspecified (DepMap=ACH-001518).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Unspecified (PubMed=15053063).
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Discontinued: JCRB; NIHS0395; true.
CC   Derived from site: In situ; Endometrium; UBERON=UBERON_0001295.
ST   Source(s): DepMap=ACH-001518; JCRB=JCRB1124; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 8,11
ST   D16S539: 9
ST   D18S51: 17,25
ST   D19S433: 14,16.2
ST   D21S11: 29
ST   D2S1338: 20,21
ST   D3S1358: 17
ST   D5S818: 11,12
ST   D7S820: 10,12
ST   D8S1179: 14
ST   FGA: 23,25
ST   Penta D: 12,13
ST   Penta E: 14,18
ST   TH01: 6,8
ST   TPOX: 11
ST   vWA: 20
DI   NCIt; C7359; Endometrial adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 24
//
RX   DOI=10.1007/978-4-431-53981-0_1;
RA   Kuramoto H., Hamano M., Imai M., Fujisawa T., Kamata Y., Arai T.,
RA   Kawaguchi M.;
RT   "HEC-1 cells: establishment of an in vitro experimental system in
RT   endometrial carcinoma.";
RL   (In) Cell and molecular biology of endometrial carcinoma; Kuramoto H., Nishida M. (eds.); pp.3-34; Springer; Tokyo (2003).
//
RX   PubMed=2064198; DOI=10.1111/j.1749-6632.1991.tb37884.x;
RA   Kuramoto H., Nishida M., Morisawa T., Hamano M., Hata H., Kato Y.,
RA   Ohno E., Iida T.;
RT   "Establishment and characterization of human endometrial cancer cell
RT   lines.";
RL   Ann. N. Y. Acad. Sci. 622:402-421(1991).
//
RX   PubMed=15053063;
RA   Kamata Y., Watanabe J., Hata H., Hamano M., Kuramoto H.;
RT   "Quantitative study on the correlation between p53 gene mutation and
RT   its expression in endometrial carcinoma cell lines.";
RL   Eur. J. Gynaecol. Oncol. 25:55-60(2004).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//